Brief: Invex Therapeutics Receives Written Response From FDA On Type C Meeting

Invex Therapeutics

15/06/2021 02:34

June 15 (Reuters) - Invex Therapeutics Ltd  IXC.AX :
    * INVEX RECEIVES WRITTEN RESPONSE FROM FDA ON TYPE C MEETING
ON
PHASE III CLINICAL TRIAL DESIGN FOR PRESENDIN (EXENATIDE)
    * FDA RECOMMENDED INVEX CONSIDER A CLINICALLY MEANINGFUL
EFFECT ON
VISUAL FUNCTION
    * INTENDS TO MEET WITH REGULATORY AND CLINICAL ADVISORS IN
COMING
WEEKS TO BETTER UNDERSTAND RESPONSE FROM FDA

Source text for Eikon:  ID:nASX591P6L 
Further company coverage:  IXC.AX